Akouos
About Akouos
Akouos is a biotechnology company focused on restoring and preserving hearing. Akouos’s scientific founders are world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy
YEAR FOUNDED:
2017
LEADERSHIP:
Founder & CEO: Dr. Manny Simons
5 articles with Akouos
-
Case Western Reserve University and Akouos sign exclusive licensing agreement to advance development of gene therapy technology as a potential treatment for a type of Usher syndrome
9/8/2019
Case Western Reserve University and Boston-based Akouos have entered into an exclusive licensing agreement to develop a patented gene therapy with the potential to treat hearing loss associated with a type of Usher syndrome, the most common deaf-blind disorder.
-
Akouos Announces Executive Leadership Team Appointments
9/3/2019
Gregory Robinson, Ph.D., Appointed to Chief Scientific Officer Co-Founder Michael McKenna, M.D., Expands Role to Full-Time Chief Medical Officer
-
Akouos to Participate in Upcoming Investor Conferences - Aug. 9, 2019
8/9/2019
Akouos announced management will be attending the following investor conferences in August
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
-
Akouos, based in Boston, announced a Series A financing worth $50 million. The round was led by seed investors 5AM Ventures and New Enterprise Associates (NEA).